How to select outcome measurement instruments for outcomes included in a “Core Outcome Set” – a practical guideline by unknown
RESEARCH Open Access
How to select outcome measurement
instruments for outcomes included in a
“Core Outcome Set” – a practical guideline
Cecilia A. C. Prinsen1*, Sunita Vohra2,3,4, Michael R. Rose5, Maarten Boers1,6, Peter Tugwell7, Mike Clarke8,
Paula R. Williamson9 and Caroline B. Terwee1
Abstract
Background: In cooperation with the Core Outcome Measures in Effectiveness Trials (COMET) initiative, the
COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) initiative aimed to
develop a guideline on how to select outcome measurement instruments for outcomes (i.e., constructs or
domains) included in a “Core Outcome Set” (COS). A COS is an agreed minimum set of outcomes that should be
measured and reported in all clinical trials of a specific disease or trial population.
Methods: Informed by a literature review to identify potentially relevant tasks on outcome measurement
instrument selection, a Delphi study was performed among a panel of international experts, representing diverse
stakeholders. In three consecutive rounds, panelists were asked to rate the importance of different tasks in the selection
of outcome measurement instruments, to justify their choices, and to add other relevant tasks. Consensus was defined
as being achieved when 70 % or more of the panelists agreed and when fewer than 15 % of the panelists disagreed.
Results: Of the 481 invited experts, 120 agreed to participate of whom 95 (79 %) completed the first Delphi
questionnaire. We reached consensus on four main steps in the selection of outcome measurement instruments
for COS: Step 1, conceptual considerations; Step 2, finding existing outcome measurement instruments, by means
of a systematic review and/or a literature search; Step 3, quality assessment of outcome measurement instruments, by
means of the evaluation of the measurement properties and feasibility aspects of outcome measurement instruments;
and Step 4, generic recommendations on the selection of outcome measurement instruments for outcomes included
in a COS (consensus ranged from 70 to 99 %).
Conclusions: This study resulted in a consensus-based guideline on the methods for selecting outcome measurement
instruments for outcomes included in a COS. This guideline can be used by COS developers in defining how to
measure core outcomes.
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Background
There is a lack of consensus with regard to the selection
of outcomes (i.e., constructs or domains) and outcome
measurement instruments (OMIs) for clinical trials [1]. As
a result, different outcomes are assessed and a variety of
OMIs (e.g., assessments by health professionals, bio-
markers, clinical rating scales, imaging tests, laboratory
tests, patient questionnaires, and performance-based tests)
measure the same outcome, causing inconsistencies in
reporting and difficulties in comparing and combining the
findings in systematic reviews and meta-analyses [2, 3]. In
addition, the quality of OMIs varies considerably, and it is
usually not apparent that the most reliable and valid OMI
has been selected. Standardization of the selection of out-
comes and OMIs is needed.
The current project is a joint initiative between the
COnsensus-based Standards for the selection of health
Measurement INstruments (COSMIN) initiative [4] and
the Core Outcome Measures in Effectiveness Trials
(COMET) initiative [5]. COSMIN aims to improve the
selection of OMIs, and has developed methodological
standards for studies on the measurement properties of
OMIs [6]. COMET aims to facilitate the development
and application of agreed standardized sets of outcomes,
also known as “Core Outcome Sets” (COS). A COS is an
agreed minimum set of outcomes that should be mea-
sured and reported in all clinical trials of a specific dis-
ease or trial population. It is a recommendation of what
should be measured and reported in all clinical trials [7].
Once a COS is defined, it is then important to achieve
consensus on how these outcomes should be measured,
i.e., which OMIs should be selected. In the selection of
OMIs, a number of tasks need to be performed. For
example, a literature search to find potentially relevant
OMIs, and a quality assessment to evaluate the (methodo-
logical) quality of the available OMIs. However, in addition
to existing and valuable expert-based guidelines, such as
the HOME Roadmap [8] and the OMERACT Handbook
[http://www.omeract.org/], a consensus-based guideline on
OMI selection is missing.
The primary aim of this study was to develop a guideline
on how to select OMIs for outcomes included in a COS.
However, a COS is not usually specific for any given clinical
trial. A clinical trial may impose additional requirements for
selecting OMIs perhaps relating to feasibility or sensitivity.
We therefore had a secondary aim of investigating whether
the methods for selecting OMIs for a COS are similar to the
methods for selecting OMIs for individual clinical trials.
Methods
As details on the methods and design have been pub-
lished previously [9], this section is restricted to a
summary.
Study design
A Delphi study was performed to achieve consensus on
relevant tasks that need to be performed in the process
of selecting OMIs for outcomes (i.e., constructs or do-
mains) included in a COS. The resulting guideline is
based on the results of the Delphi study. Also, existing
methodology that has been developed by COSMIN for
performing systematic reviews of OMIs was used to sup-
port the guideline [4] as well as methodology that stems
from the Outcome Measures in Rheumatology (OMER-
ACT) Filter 2.0 and the OMERACT Handbook for devel-
oping COSs for rheumatic diseases [10, 11], and the
Primary Outcomes Reporting in Trials (PORTal) initia-
tive which looks at primary outcomes reported in adult
and pediatric clinical trials [12]. These other sources of
evidence were used to expand on items to a level not
discussed in the Delphi study.
Literature review
To inform the Delphi study, a literature review was per-
formed to identify existing studies that provide guidance
on OMI selection. A health research librarian conducted
an electronic literature search in November 2012 in
MEDLINE, EMBASE, PsycINFO, and Cinahl.
Inclusion criteria: studies that were guidelines, meta-
analyses, review articles, or systematic reviews, and study
protocols that developed or applied methodology for
selecting outcomes or OMIs to be used in clinical trials.
Exclusion criteria: studies that discussed “how to meas-
ure” rather than “how to select” outcomes or OMIs for
use in clinical trials; and studies that aimed to evaluate
the measurement properties of OMIs.
All search strategies are presented in Additional file 1.
Development of the Delphi questionnaire
The potentially relevant tasks on OMI selection identi-
fied from the literature review were included in the Del-
phi questionnaire. Questions were formulated on the
relevance of each of the tasks, for example: “Should COS
developers agree upon the target population before start-
ing to search for outcome measurement instruments?”
Response options included “highly recommended,”
“desirable,” “not relevant,” and “not my expertise.” Free
text boxes were included after each question to facilitate
comments.
Selection of experts
Experts who were identified from the literature review,
as well as experts who participated in a previous COS-
MIN Delphi study [13], were invited to participate. A
“snowball sampling” approach was used to identify other
potential experts. We found no guidelines for sample
sizes of Delphi studies, but in general having more pan-
elists will facilitate acceptance and implementation of
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the guideline [14]. Based on our previous experiences
with Delphi studies [6, 13, 15, 16], we anticipated a re-
sponse rate of between 30 and 40 %. We therefore in-
vited all 481 previously identified experts to participate.
Delphi rounds
The Delphi study was planned to consist of three ques-
tionnaire rounds in order to achieve consensus [17].
Panelists were asked to anonymously rate the relevance
of different tasks on OMI selection. They were encour-
aged to justify their choices and to add other possibly
relevant tasks. Subsequently, panelists were asked for
their opinion on whether the methods for selecting
OMIs for a COS are similar to the methods for selecting
OMIs for individual clinical trials.
Consensus was defined as being achieved when at least
70 % of the panelists agreed with a task (i.e., highly rec-
ommended or desirable) with no opposing arguments
provided, and when fewer than 15 % of the panelists dis-
agreed with a task (i.e., “not relevant”). Tasks on which
such consensus was reached were included in the guide-
line and panelists were not asked to vote for these tasks
again. When at least 50 % of the panelists disagreed with
a task (i.e., “not relevant”) and when no strong argu-
ments in favor of this task were given, we excluded the
task from the guideline. Tasks with an indeterminate re-
sponse were taken to the subsequent round. When con-
sensus was not reached after the third round, the need
for a fourth questionnaire round was considered by the
Delphi Steering Committee (CP, SV, MR, and CT).
Data analysis
Data were analyzed both quantitatively (absolute values,
percentages) and qualitatively (listings of the comments
and suggestions given by the panelists). Based on the re-
sponses given in the first round, including the comments
given in the free text boxes, new proposals were formu-
lated. Response options included –“strongly agree,”
“agree,” “no opinion,” “disagree,” and “strongly disagree.”
Additionally, new questions that arose based on the
comments given were formulated and were marked as
“new questions.” Panelists were asked to rate their agree-
ment on the given proposals and the relevance of the
new tasks in the second round. The results of the second
round were then again analyzed for consensus following
the same procedure as for the first round [9].
Results
Study population
A total of 481 experts were invited to participate. Deliv-
ery failed to 41 recipients and four “out of office” notifi-
cations were received concerning long-term absence. A
total of 120/436 panelists (28 %) accepted the invitation.
95/120 panelists (79 %), from 14 different countries,
completed the first Delphi questionnaire (Table 1). The
second questionnaire was completed by 65/95 (68 %),
and 76/95 (80 %) completed the third questionnaire.
Delphi rounds
In the first round, panelists were asked to rate 78 ques-
tions. Consensus was reached on 58 questions (74 %).
In the second round, panelists were asked to rerate 20
questions on which no consensus was achieved in the
first round. In addition, 19 new questions were formu-
lated based on the additional comments invited in the
first round. For 2/19 new questions, a 70 % or greater
consensus was not reached (67 %1 and 48 %2, respect-
ively). For 7/19 questions, consensus was reached (range
71 to 84 %) but 15 % or more of the panelists disagreed.
In reviewing the panelists’ comments on these items, it
was clear that for a total of eight questions we were too
restrictive in our formulations, too brief in the descrip-
tions of the tasks, or that certain tasks might not be ap-
plicable in all circumstances.
In the third round, panelists were provided with eight
new formulations, instead of questions, of the paragraph
for potential inclusion in the guideline intending to ad-
dress nuances applicable to specific situations. For ex-
ample, in the first round it was suggested that the
selection of OMIs should always be guided by a review
of the face validity of an OMI. In the second round, pan-
elists were asked if COS developers themselves should
assess the face validity of an outcome measurement in-
strument to be included in a COS. Eighty-four percent
of the panelists agreed; however, 16 % of them (strongly)
disagreed. It was argued that only if no face validity as-
sessment is reported in the literature, COS developers
should do it themselves. In the third round, we proposed
the following recommendation for the guideline: “It is
recommended that, in case no face validity assessment is
reported in the literature, COS developers assess the face
validity of an OMI to be included in a COS.” On all
eight formulations of the paragraph for potential inclu-
sion in the guideline consensus was reached (range 81 to
93 %), but 15 % or more of the panelists disagreed on
three of these formulations (15 %, 15 %, and 19 %, re-
spectively). As no opposing arguments were provided
against these three formulations, the Steering Commit-
tee decided to include all eight proposed formulations in
the guideline.
We reached consensus on four main steps in the selec-
tion of OMIs for outcomes included in a COS (Table 2).
Each of these four steps includes a variety of tasks.
Step 1. Conceptual considerations
We reached 98–99 % consensus that the first step in the
selection of OMIs is to agree in detail upon the con-
struct (i.e., outcome or domain) to be measured [11] and
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the target population (e.g., age, gender, disease charac-
teristics) (Table 2). This is a key task of the group devel-
oping a COS for which OMIs are sought.
Step 2. Finding existing outcome measurement
instruments
We reached 70–99 % consensus that the second step is
to find existing OMIs. With the intention to search for
all existing OMIs, three sources of information can be
used: (1) systematic reviews, (2) literature searches, and
(3) other sources, considered as optional (Table 2). The
COSMIN guideline for systematic reviews of OMIs rec-
ommends that those searching the literature for all
OMIs do not use search terms to cover “type of OMI”
because a wide variety of terminology is used (e.g., OMIs
are also termed measures, methods, questionnaires,
tests, etc.). This variety of terms that has been used in
the original articles can lead to a high risk of missing
relevant studies [4]. There is, however, one exception for
patient-reported outcome measures (PROMs): for these
a comprehensive PROM filter, developed for PubMed by
the Patient Reported Outcomes Measurement Group of
the University of Oxford, can be used. This search filter
is available through the COSMIN website [18]. In all
other cases it is recommended to only use search terms
for “construct,” “population,” and “measurement proper-
ties” in the search for all OMIs [4].
Step 3. Quality assessment of outcome measurement
instruments
We reached 70–97 % consensus that the third step in
the selection of OMIs is quality assessment of the avail-
able OMIs. According to COSMIN, this includes two
distinctive parts: (1) evaluation of the methodological
quality of the included studies by using the COSMIN
Table 1 Characteristics of the panelists


















Current profession, number (%)c
Clinician 26 (27)
Journal editor 9 (10)
Researcher 88 (93)
Othere 10 (11)
Level of experience in COS development, number (%)
A lot 11 (12)
Some 28 (30)
A little 26 (27)
None 30 (32)
Level of experience in instrument development, number (%)
A lot 32 (34)
Some 39 (41)
A little 12 (13)
None 12 (13)
Level of experience with evaluation of measurement properties,
number (%)
A lot 44 (46)
Some 33 (35)
A little 14 (15)
None 4 (4)
Table 1 Characteristics of the panelists (Continued)
Level of experience in conducting systematic reviews, number (%)
A lot 20 (21)
Some 35 (37)
A little 19 (20)
None 21 (22)
aIn some cases, the total numbers are not exactly 100 % because of rounding
of percentages to no decimal places
bBrazil (N = 1), France (N = 2), Italy (N = 3), Norway (N = 1), Portugal (N = 1),
Switzerland (N = 1)
cAs panelists could tick more than one response option, the total score
exceeded 100 %
dTrialist (N = 2), systematic reviewer (N = 1), social research methodologist
(N = 2), clinical academic (N = 1), scientific researcher (N = 1), health services
researcher (N = 1), clinical psychologist (N = 2), project manager (N = 1), public
health (N = 1), academic course writer/teacher (N = 1), clinical researcher
(N = 1), human movement scientist (N = 1)
eAcademic (N = 2), consultant for clinical researches (N = 1), research funder
(N = 1), Health Technology Assessment consultant (N = 2), educator
(N = 1), project manager (N = 1), advisor on research methods (N = 1), director
of collaborative centre (N = 1)
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checklist [6] and (2) evaluation of the quality of the
OMIs (i.e., their measurement properties and feasibility
aspects) by applying criteria for good measurement
properties (Table 2) [19].
Following the COSMIN taxonomy on which inter-
national consensus was reached [6, 13], all nine meas-
urement properties were considered relevant in the
selection process of OMIs for outcomes included in a
COS (Table 3). Consensus was achieved on the criteria
for good measurement properties (Table 4). The quality
assessment applies to all different types of OMIs, such
as assessments by health professionals, biomarkers, clin-
ical rating scales, imaging tests, laboratory tests, patient
questionnaires, and performance-based tests, and the ap-
plicable measurement properties should be evaluated.
In the evaluation of the measurement properties of the
OMIs that could potentially be included in a COS, COS-
MIN recommends a predefined order of importance of
evaluating the measurement properties: (1) content val-
idity, (2) internal structure (i.e., structural validity and
internal consistency, and/or Item Response Theory
(IRT)/Rasch model fit), and where applicable (3) the
remaining measurement properties (i.e., reliability, meas-
urement error, hypotheses testing, cross-cultural validity,
criterion validity, and responsiveness). Content validity is
considered to be the most important measurement
Table 2 Consensus on four main steps in the selection of outcome measurement instruments for Core Outcome Sets (COSs),
including their tasks
Percentage of agreement in the
Delphi study (%)
Step 1. Conceptual considerations
Aspects to consider before starting to search for outcome measurement instruments:
1. The construct (i.e., outcome or domain) to be measured 98
2. The target population (e.g., age, gender, disease characteristics) 99
Step 2. Finding existing outcome measurement instruments
COS developers should aim for finding all existing outcome measurement instruments. 72
When finding outcome measurement instruments, COS developers can have three sources of information:
(1) systematic reviews, (2) literature searches, and (3) other sources (optional)
1. COS developers use existing, good quality, and up-to-date systematic reviews of outcome measurement
instruments
94
2 a. MEDLINE (e.g., through the PubMed or OVID interface) is considered the minimum database to consult in
finding all existing outcome measurement instruments. An additional search in EMBASE is highly
recommended
99 and 82, respectively
b. Reference lists of the included studies should be checked to find all existing outcome measurement
instruments
91
3. Additional sources may be considered as optional sources in finding relevant outcome measurement
instruments
89
Step 3. Quality assessment of outcome measurement instruments
To evaluate the quality of the outcome measurement instruments, COS developers evaluate (1) the
measurement properties and (2) the feasibility aspects of the identified outcome measurement instruments
1. Evidence on the measurement properties should be available in the target populationa 70–93
2. Feasibility aspects should be taken into consideration in the selection of outcome measurement
instruments for outcomes included in a COSb
77–97
Step 4. Generic recommendations on the selection of outcome measurement instruments for a COS
1. Select only one outcome measurement instrument for each outcome (e.g., construct or domain) in a COS 90
2. The minimum requirements for including an outcome measurement instrument in a COS are: at least high
quality evidencec for goodd content validity and for goodd internal consistency (if applicable), and if the
outcome measurement instrument is feasible
81
3. A consensus procedure to agree on the outcome measurement instruments for each outcome included in
a COS should be performed among all relevant stakeholders, including patients
90
aSee Table 3 for the percentage of agreement per measurement property separately
bSee Table 6 for the percentage of agreement per feasibility aspect separately
c“High quality evidence” is defined as consistent findings in multiple studies of at least good quality OR in one study of excellent quality AND a total sample size
of 100 patients or more (Table 5)
d“Good” is defined as a “+” rating according to the criteria for good measurement properties (Table 4)
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property of an OMI because if it is unclear what the
OMI is actually measuring, the assessment of the other
measurement properties is not valuable. If the content
validity of an OMI is poor or unknown, the OMI will
not be further considered in the selection process. Subse-
quently, the internal structure (i.e., internal consistency
and structural validity) should be evaluated. In case there
is evidence that the internal structure of an OMI is poor,
the OMI will not be further considered, i.e., the other
measurement properties (including reliability, measure-
ment error, hypotheses testing, cross-cultural validity,
criterion validity, and responsiveness) will not be further
evaluated [4].
To reach a conclusion about the overall quality of an
OMI, an overall evaluation of the OMI should be con-
structed, based on all available evidence [20]. This can
be done by a best-evidence synthesis, where the quality
of evidence should be graded for a body of evidence for
each measurement property, taking into account the
number of studies, the methodological quality of the
studies, and the consistency of the results of the meas-
urement properties (Table 5) [4].
We reached 77–97 % consensus that COS developers
should take feasibility aspects into consideration in the se-
lection of OMIs for outcomes included in a COS (Table 6).
Step 4. Generic recommendations on the selection of
outcome measurement instruments for a COS
We reached 81–90 % consensus on three generic recom-
mendations concerning the final decision-making on in-
cluding an OMI in a COS: (1) it is recommended to
select only one OMI for each outcome (i.e., constructs
or domains) in a COS, which will enhance the compar-
ability of clinical trials, (2) it is recommended that an
OMI can be provisionally included in a COS if there is
at least high quality evidence3 for good4 content validity
and good4 internal consistency (or evidence for test-
retest or interrater reliability) and if the OMI is feasible,
and (3) it is recommended that COS developers use a
consensus procedure to get final agreement on the se-
lected OMIs included in a COS among relevant stake-
holders, including patients (Table 2).
Following the OMERACT Handbook, the next phase
of research needs to be more explicit on what categories
of stakeholders should be considered (patients, public,
practitioner, press, policy-maker, program manager, pro-
fessor, payer) and what the minimum requirements are
for consensus [10, 11].
In addition, we reached 95 % consensus that, in gen-
eral, the methods for the selection of OMIs for a COS
are considered to be similar to the methods for selecting
OMIs for individual clinical trials. However, as in prac-
tice it may not be feasible to perform all these steps for
a clinical trial, trialists can then chose to use those OMIs
that are included in a COS.
The four main steps, including their tasks, were in-
cluded in the final guideline that can be found in Add-
itional file 2.
Discussion
The present guideline on methods for selecting OMIs
can be used by COS developers in defining how to
measure the core outcomes (i.e., constructs or domains)
that are included in a COS. The guideline is based on
Table 3 Overview of all measurement properties, including their definitions
Measurement property Definition according to the COSMINa taxonomy Percentage of agreement
in the Delphi study (%)
Content validity (including face
validity)
The degree to which the content of a measurement instrument is an
adequate reflection of the construct to be measured
93
Reliability The degree to which the measurement is free from measurement error 91
Responsiveness The ability of a measurement instrument to detect change over time in
the construct to be measured
91
Internal consistency The degree of interrelatedness among the items 90
Structural validity The degree to which the scores of a measurement instrument are an
adequate reflection of the dimensionality of the construct to be measured
83
Measurement error The systematic and random error of a patient’s score that is not attributed
to true changes in the construct to be measured
83
Hypotheses testing The degree to which the scores of a measurement instrument are
consistent with hypotheses based on the assumption that the measurement
instrument validly measures the construct to be measured
82
Criterion validity The degree to which the scores of a measurement instrument are an
adequate reflection of a “gold standard”
76
Cross-cultural validity The degree to which the performance of the items on a translated or
culturally adapted measurement instrument is an adequate reflection of the
performance of the items of the original version of the measurement instrument
70
a COnsensus-based Standards for the selection of health Measurement INstruments
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Table 4 Criteria for good measurement properties
Measurement property Rating* Criteria Percentage of agreement
in the Delphi study (%)
Content validity
(including face validity)
+ All items refer to relevant aspects of the construct to be measured AND are
relevant for the target population AND are relevant for the context of use AND
together comprehensively reflect the construct to be measured
97
? Not all information for ‘+’ reported
– Criteria for ‘+’ not met
Structural validity + CTT:
Unidimensionality: EFA: First factor accounts for at least 20% of the variability AND
ratio of the variance explained by the first to the second factor greater than 4 OR
Bi-factor model: Standardized loadings on a common factor >0.30 AND correlation
between individual scores under a bi-factor and unidimensional model >0.90





At least limited evidence for unidimensionality or positive structural validity AND no
evidence for violation of local independence: Rasch: standardized item-person fit
residuals between -2.5 and 2.5; OR IRT: residual correlations among the items after
controlling for the dominant factor < 0.20 OR Q3's < 0.37 AND no evidence for
violation of monotonicity: adequate looking graphs OR item scalability >0.30 AND
adequate model fit: Rasch: infit and outfit mean squares ≥ 0.5 and ≤ 1.5 OR Z-
standardized values > -2 and <2; OR IRT: G2 >0.01;
Optional additional evidence:
Adequate targeting; Rasch: adequate person-item threshold distribution; IRT:
adequate threshold range
No important DIF for relevant subject characteristics (such as age, gender,
education), McFadden's R2 < 0.02
? CTT: Not all information for ‘+’ reported
IRT: Model fit not reported
– Criteria for ‘+’ not met
Internal consistency + At least limited evidence for unidimensionality or positive structural validity AND
Cronbach's alpha(s) ≥ 0.70 and ≤ 0.95
89
? Not all information for ‘+’ reported OR conflicting evidence for unidimensionality or
structural validity OR evidence for lack of unidimensionality or negative structural validity
– Criteria for ‘+’ not met
Reliability + ICC or weighted Kappa ≥ 0.70 88
? ICC or weighted Kappa not reported
– Criteria for ‘+’ not met
Measurement error + SDC or LoA < MIC 72
? MIC not defined
– Criteria for ‘+’ not met
Hypotheses testing + At least 75% of the results are in accordance with the hypotheses 87
? No correlations with instrument(s) measuring related construct(s) AND no
differences between relevant groups reported
– Criteria for ‘+’ not met
+ No important differences found between language versions in multiple group
factor analysis or DIF analysis
Cross-cultural validity ? Multiple group factor analysis AND DIF analysis not performed 84
– One or more criteria for ‘+’ not met
Criterion validity + Convincing arguments that gold standard is “gold” AND correlation with gold
standard ≥ 0.70
88
? Not all information for ‘+’ reported
– Criteria for ‘+’ not met
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the results of the Delphi study, the methodology derived
from the COSMIN initiative, and recommendations
from OMERACT [11]. With this stepwise approach, we
intend to optimize the methodology of selecting OMIs
for outcomes included in a COS. The field of COS
development is relatively new but rapidly growing;
COMET maintains a database with the aim of including
all registered and ongoing initiatives on COS develop-
ment including, for example, the Harmonizing Outcome
Measures for Eczema (HOME), and the Initiative on
Methods, Measurement, and Pain Assessment in Clinical
Trials (IMMPACT) initiatives. Currently, this database
includes 249 published COS studies that relate to 300
COS, and 144 ongoing COS studies [5, 21]. Other exam-
ples of the potential impact of COSs are that the
National Institute for Health Research’s (a UK research
funding body) Health Technology Assessment program,
requires COSs to be considered in the funding applica-
tions of clinical trials, and that Cochrane and Grading of
Recommendations Assessment, Development and Evalu-
ation (GRADE) are encouraging the use of COSs in re-
views and clinical practice guidelines. We believe that
methodology guidelines should be based on the agreed
methodology so as to deliver high-quality COSs that can
be used in future clinical trials and other research. Using
high-quality COSs will ultimately improve the conduct
and reporting of clinical trials, enhance the value of evi-
dence synthesis by reducing heterogeneity between tri-
als, and may reduce outcome reporting bias. COSs
reflect the best evidence at the time. However, as the
field of COS development is continuously evolving (e.g.,
existing OMIs are further tested and new ones are being
developed), the OMIs included in a COS might be
reconsidered and/or replaced in light of new evidence.
There may be good reasons for COS developers to de-
viate from the guideline. For example, OMERACT wants
responsiveness to be assessed before inclusion in a
provisional core set, whereas we reached consensus for
at least high quality evidence for good content validity
and for good internal consistency. Another example is
that, although a Cronbach’s alpha of >0.95 usually
indicates item redundancy, there may be good reasons
to retain certain potentially redundant items in a ques-
tionnaire. Also, we realize that in practice not all steps
might be feasible within a given time frame or budget.
We recommend that COS developers should decide
what is feasible in their time frame and within their
budget.
Although the methods for the selection of OMIs for a
COS are considered to be similar to the methods for
selecting OMIs for individual clinical trials, it was ar-
gued that a higher standard for selecting OMIs for a
COS may be justified. Furthermore, it may not be feas-
ible to perform all these steps for a clinical trial. This
underlines the importance of the development of COSs,
as trialists can then chose to use those OMIs that are in-
cluded in a COS. When the primary outcome of a clin-
ical trial is not a core outcome, the COS still needs to be
measured. However, trialists could apply these recom-
mendations to select the OMI for their primary
outcome.
We acknowledge the limitations that might arise be-
cause of the relatively low response rate to the initial in-
vitation of our Delphi study. As the results of Delphi
Table 4 Criteria for good measurement properties (Continued)
Responsiveness + At least 75% of the results are in accordance with the hypotheses 88
? No correlations with changes in instrument(s) measuring related construct(s) AND
no differences between changes in relevant groups reported
– Criteria for ‘+’ not met
Modified from Terwee et al. [19]
AUC = area under the curve, CFI = comparative fit index, CTT = classical test theory, DIF = differential item functioning, EFA = exploratory factor analysis,
ICC = intraclass correlation coefficient, IRT = item response theory, LoA = limits of agreement, MIC = minimal important change, RMSEA = root mean square error
of approximation, SEM = Standard Error of Measurement, SDC = smallest detectable change, SRMR = standardized root mean residuals, TLI = Tucker-Lewis index
* “+” = positive rating, “?” = indeterminate rating,” –“ = negative rating
Table 5 Quality of evidence
Quality rating Criteria
High Consistent findings in multiple studies of at least good quality OR one study of excellent quality
AND a total sample size of ≥100 patients
Moderate Conflicting findings in multiple studies of at least good quality OR consistent findings in multiple studies of at least
fair quality OR one study of good quality AND a total sample size of ≥50 patients
Low Conflicting findings in multiple studies of at least fair quality OR one study of fair quality AND a total
sample size of ≥30 patients
Very low Only studies of poor quality OR a total sample size of <30 patients
Unknown No studies
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studies in general are highly dependent upon the com-
position of the panel, we aimed to include a sample of
experts who represent diverse disciplines, institutes and
organizations and reflect the population that is intended
to use a guideline for OMI selection. However, it is diffi-
cult to examine the representativeness of the panelists as
it is impossible to draw a random sample from all ex-
perts. Experts were, therefore, selected nonsystemati-
cally, which may be considered as a limitation of our
Delphi study. Another limitation of our study is that we
did not include patient research partners in the Delphi
process. We acknowledge that, herewith, we may have
omitted their contribution to the selection of OMIs.
Conclusions
This consensus-based guideline on the methods for select-
ing OMIs for outcomes included in a COS can be used by
COS developers and clinical trialists to define how to
measure core outcomes (i.e., constructs or domains) for
any diseases or other condition in health and social care.
Endnotes
1Question: “The minimum standard for internal
consistency of outcome measurement instruments to be
included in a COS should be a Cronbach’s alpha of be-
tween 0.70 and 0.90.”
2Question: “If no outcome measurement instrument
exists that meets the requirements for adequate
measurement properties, it can be included in a COS
“conditionally.” What should be the minimum condition
before an instrument can be included in a COS?”
3“High quality evidence” is defined as consistent find-
ings in multiple studies of at least good quality OR in
one study of excellent quality AND a total sample size of
100 patients or more (Table 5)
4“Good” is defined as a “+” rating according to the cri-
teria for good measurement properties (Table 4)
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Table 6 Overview of all feasibility aspects
Feasibility aspects Percentage of agreement
in the Delphi study (%)
Patient’s comprehensibility 97
Interpretability 95
Ease of administration 93




Patient’s mental ability level 91
Ease of standardization 90
Clinician’s comprehensibility 90
Type of outcome measurement instrument 90




Type of administration 87
Availability in different settings 86
Copyright 85
Patient’s physical ability level 85
Regulatory agency’s requirement for approval 84
Ease of score calculation 77
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